Promoting consumers access to affordable medicines, the Delhi High Court...rejected pharma MNC Bayer's petition, which had indirectly sought ‘patent linkage'... patent linkages mean that no marketing approval is given for generic versions of medicines, which have been granted a patent in India...While holding that unpatented drugs are not spurious drugs, Justice Ravindra Bhat held that this petition was an attempt to tweak public policy. [refers to Cipla]